share_log

SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)

SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)

SciSparc | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/11/04 16:04

Moomoo AI 已提取核心訊息

SciSparc reported revenue of $840,000 for H1 2024, down from $1.97M in H1 2023, primarily from its Wellution brand nutraceutical business. Operating loss increased 19% to $3.53M, driven by higher R&D expenses of $841,000 and G&A costs of $2.63M. The company ended the period with $2.62M in cash.The company has undertaken several strategic initiatives, including signing an LOI to spin off its pharmaceutical portfolio, entering a patent license agreement for SCI-160, and advancing a merger with AutoMax Motors. SciSparc extended a $4.25M bridge loan to AutoMax and secured a $20M standby equity purchase agreement with YA II PN.Looking ahead, SciSparc plans to sell its 52.73% stake in MitoCareX Bio to a U.S. public company for up to $7M based on milestones. Management indicates additional capital will be required to fund operations and complete product development, with no significant pharmaceutical revenue expected in the near term.
SciSparc reported revenue of $840,000 for H1 2024, down from $1.97M in H1 2023, primarily from its Wellution brand nutraceutical business. Operating loss increased 19% to $3.53M, driven by higher R&D expenses of $841,000 and G&A costs of $2.63M. The company ended the period with $2.62M in cash.The company has undertaken several strategic initiatives, including signing an LOI to spin off its pharmaceutical portfolio, entering a patent license agreement for SCI-160, and advancing a merger with AutoMax Motors. SciSparc extended a $4.25M bridge loan to AutoMax and secured a $20M standby equity purchase agreement with YA II PN.Looking ahead, SciSparc plans to sell its 52.73% stake in MitoCareX Bio to a U.S. public company for up to $7M based on milestones. Management indicates additional capital will be required to fund operations and complete product development, with no significant pharmaceutical revenue expected in the near term.
SciSparc報告2024年上半年的營業收入爲840,000美元,較2023年上半年的197萬下降,主要來自其Wellution品牌的營養保健業務。由於研發費用增加至841,000美元以及一般管理費用增加至263萬,運營損失增加了19%,達到了353萬。公司結束時現金爲262萬。該公司採取了幾個戰略舉措,包括簽署意向書剝離其藥品組合、與SCI-160簽署專利許可協議以及推進與AutoMax Motors的合併。SciSparc向AutoMax提供了425萬的過渡貸款,並與YA II PN達成了2000萬的備用股權購買協議。展望未來,SciSparc計劃將其在MitoCareX Bio的52.73%的股權出售給一家美國上市公司,金額最高可達700萬,具體依據里程碑。管理層表示,業務運營和完成產品開發需要額外資金,近期預計不會有顯著的藥品營業收入。
SciSparc報告2024年上半年的營業收入爲840,000美元,較2023年上半年的197萬下降,主要來自其Wellution品牌的營養保健業務。由於研發費用增加至841,000美元以及一般管理費用增加至263萬,運營損失增加了19%,達到了353萬。公司結束時現金爲262萬。該公司採取了幾個戰略舉措,包括簽署意向書剝離其藥品組合、與SCI-160簽署專利許可協議以及推進與AutoMax Motors的合併。SciSparc向AutoMax提供了425萬的過渡貸款,並與YA II PN達成了2000萬的備用股權購買協議。展望未來,SciSparc計劃將其在MitoCareX Bio的52.73%的股權出售給一家美國上市公司,金額最高可達700萬,具體依據里程碑。管理層表示,業務運營和完成產品開發需要額外資金,近期預計不會有顯著的藥品營業收入。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息